178 related articles for article (PubMed ID: 30698093)
1. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
[TBL] [Abstract][Full Text] [Related]
2. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders.
Nazareth T; Ko JJ; Sasane R; Frois C; Carpenter S; Demean S; Vegesna A; Wu E; Navarro RP
J Manag Care Spec Pharm; 2017 Oct; 23(10):1018-1026. PubMed ID: 28944734
[TBL] [Abstract][Full Text] [Related]
5. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
6. A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers.
Kamal KM; Covvey JR; Dashputre A; Ghosh S; Shah S; Bhosle M; Zacker C
J Manag Care Spec Pharm; 2017 Feb; 23(2):136-162. PubMed ID: 28125370
[TBL] [Abstract][Full Text] [Related]
7. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
Waldeck AR; Botteman MF; White RE; van Hout BA
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
[TBL] [Abstract][Full Text] [Related]
8. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
[TBL] [Abstract][Full Text] [Related]
9. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
Westrich K; Buelt L; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
[TBL] [Abstract][Full Text] [Related]
10. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
[TBL] [Abstract][Full Text] [Related]
11. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
[TBL] [Abstract][Full Text] [Related]
12. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
Schafer J; Galante D; Shafrin J
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies.
Brixner D; Woodward TC; Seifter N; Biskupiak J; Marciniak M; Neumann P; Oderda G
J Manag Care Spec Pharm; 2019 Feb; 25(2):164-173. PubMed ID: 30698089
[TBL] [Abstract][Full Text] [Related]
15. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
[TBL] [Abstract][Full Text] [Related]
16. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
17. Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.
Garrison LP; Jackson T; Paul D; Kenston M
J Manag Care Spec Pharm; 2019 Jul; 25(7):793-799. PubMed ID: 30784347
[TBL] [Abstract][Full Text] [Related]
18. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
[No Abstract] [Full Text] [Related]
19. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
[TBL] [Abstract][Full Text] [Related]
20. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]